We examined the ability of partially synthesized new compounds from fangchinoline and tetrandrine to reverse P-glycoprotein (P-gp)-dependent multidrug resistance (MDR) in vitro and in vivo. All compound enhanced the in vitro cyctotoxic effect of vinblastin (VBL) at 0.1 μM as potent as 10 μM verapamil against the resistant cell line P388/ADR. The combination effect tended to be strong by substitution of bulky group, resulting 5,14-dibromotetrandrine (compound #9) showed the strongest effect. Compound #9 increased intracellular VBL accumulation in P388/ADR cells, much stronger than verapamil, as well as cytotoxic combined effect. This mechanism seems to inhibit the function of P-gp, but not the expression of P-gp. In combination with VBL, this compound also synergistically prolonged the life-span of P388/ADR-bearing mice. Bisbenzylisoquinoline alkaloids and their derivatives are possible to be good candidates as modifier of MDR in cancer chemotherapy.
我们研究了部分合成的芳
喹啉和四
氢化可的松新化合物在体外和体内逆转P-糖蛋白(P-gp)依赖性多药耐药性(MDR)的能力。所有化合物都增强了0.1 μ
M长春新碱(VBL)的体外细胞毒性作用,其对耐药细胞株P388/ADR的作用与10 μ
M维拉帕米相同。通过取代大分子基团,联合作用趋于增强,结果 5,14-二
溴扁桃碱(化合物 #9)的作用最强。化合物 #9 增加了 P388/ADR 细胞内 VBL 的积累,比
维拉帕米强得多,同时还具有细胞毒性联合效应。这种机制似乎抑制了 P-gp 的功能,但没有抑制 P-gp 的表达。该化合物与 VBL 联用,还能协同延长 P388/ADR 小鼠的寿命。双苄基
异喹啉生物碱及其衍
生物有可能成为癌症化疗中调节 MDR 的良好候选药物。